Monthly Prescribing Reference

New Treatment for Partial-Onset Seizures Gets FDA Approval

Although its exact mechanism in the treatment of partial-onset seizures is unknown, cenobamate has been shown to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents. The Food ...
Monthly Prescribing Reference

Xcopri Now Available for Partial-Onset Seizures in Adults

SK Life Science has announced the availability of Xcopri (cenobamate) tablets for the treatment of partial-onset seizures in adults.  SK Life Science has announced the availability of Xcopri ...
Forbes

XCOPRI Reduces Number Of Partial-Onset Seizures In Adults, Earns FDA Approval

Last week, the FDA approved XCOPRI (cenobamate tablets) to treat partial-onset seizures in adults. This approval will help offer additional aid for the many individuals throughout the world who live ...
Becker's Hospital Review

FDA approves Eisai’s epilepsy drug for partial-onset seizures

The Food and Drug Administration on Wednesday approved Eisai’s epilepsy drug Fyompa as a primary treatment for partial-onset seizures in epileptic patients 12 years or older. Here are three things to ...
Healio

FDA approves XCOPRI for partial-onset seizures

Please provide your email address to receive an email when new articles are posted on . The FDA recently approved XCOPRI for adults with partial-onset seizures, its manufacturer announced. “The ...
Fox 5 San Diego

SK life science Presents Latest Data on XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AES 2022 Annual Meeting

Post-hoc analysis from open-label Phase 3 study shows treatment with cenobamate led to a reduction of concomitant anti-seizure medications (ASMs) while maintaining ≥50% and 100% seizure reduction ...
Medscape

for Focal Epilepsy

The US Food and Drug Administration (FDA) has approved cenobamate (Xcopri, SK Life Science) for the treatment of partial-onset seizures in adult patients with epilepsy. Today's approval was based on ...
Nasdaq

UCB's VIMPAT® (lacosamide) CV now approved by FDA for primary generalized tonic-clonic seizures and expanded pediatric use for people living with epilepsy

-- New approval for VIMPAT® (lacosamide) CV in the U.S. as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS) in patients four years of age and older -- All three ...
Healio

FDA approves Briviact for young children with partial-onset seizures

The FDA has approved an expanded indication for Briviact CV tablets, oral solution and injection, for treating partial-onset seizures among children as young as 1 month. “When a child or infant ...
Medscape

Lacosamide: Pharmacology, Mechanisms of Action and Pooled Efficacy and Safety Data in Partial-Onset Seizures

Vomiting 2.5 5.9 8.5 Vision blurred 2.5 2.2 8.5 Somnolence 4.7 5.2 8.1 Nasopharyngitis 5.8 6.3 7.6 Fatigue 5.8 7.0 7.2 Coordination abnormal 1.6 4.1 7.2 Tremor 4.1 3.7 6.2 Balance disorder 0.0 1.1 5.1 ...
Nasdaq

Eisai's Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures

TOKYO, Aug 2, 2021 - (JCN Newswire) - - Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) has obtained two ...
News Medical

Briviact (brivaracetam) approved for treatment of partial onset seizures in patients with epilepsy

The U.S. Food and Drug Administration yesterday approved Briviact (brivaracetam) as an add-on treatment to other medications to treat partial onset seizures in patients age 16 years and older with ...